Analgesia News and Research

RSS

NIH allocated $400 million funding for pain research in 2010

An unprecedented level of federal funding for pain research, some $400 million, was allocated in 2010 by the National Institutes of Health (NIH) through provisions of the American Recovery and Investment Act and the Affordable Care Act to help accelerate advances in pain research, prevention and treatment.

21 May 2011

APS honors recipients of Clinical Centers of Excellence in Pain Management Awards

The American Pain Society, www.ampainsoc.org, today honored the recipients of its fifth annual Clinical Centers of Excellence in Pain Management Awards recognizing the nation's outstanding pain care centers.

21 May 2011

Unigene enters Clinical Manufacturing Services Agreement with Cara Therapeutics

Unigene Laboratories, Inc. a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced today that the Company signed a Clinical Manufacturing Services Agreement with Cara Therapeutics, Inc.

19 May 2011

Daiichi Sankyo, Regency Therapeutics launch SPRIX Nasal Spray for severe pain

Regency Therapeutics, a newly established division of Luitpold Pharmaceuticals, Inc., and its co-promotion partner Daiichi Sankyo, Inc., announced today that they have launched SPRIX® (ketorolac tromethamine) Nasal Spray and that it is now commercially available.

17 May 2011

Positive results from EXPAREL Phase 3 study to be presented at ASCRS Annual Scientific Meeting

Pacira Pharmaceuticals, Inc., an emerging specialty pharmaceutical company, today announced that positive results from its Phase 3 study evaluating EXPAREL in patients following hemorrhoidectomy will be presented at the 2011 American Society of Colon and Rectal Surgeons Annual Scientific Meeting in Vancouver, British Columbia.

16 May 2011

Nuvo Research acquires ZARS Pharma

Nuvo Research Inc., a specialty pharmaceutical company dedicated to building a portfolio of products primarily for the treatment of pain, today announced that it has completed its acquisition of ZARS Pharma, Inc.

13 May 2011

Patients with sickle cell disease may require higher, frequent doses of morphine

Frequent episodes of severe pain occur in patients with sickle cell disease (SCD) and require treatment with potent opioid medications. A new study published in The Journal of Pain reports that SCD patients clear morphine from their blood stream quickly and, therefore, require high doses to achieve optimal analgesia.

13 May 2011

FDA accepts Insys NDA for Fentanyl SL Spray to treat breakthrough cancer pain

Insys Therapeutics, Inc. today announced that the Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for Fentanyl SL Spray. The FDA will notify Insys of its PDUFA date in the 74-day letter which is expected in the upcoming weeks.

12 May 2011

Pacira Pharmaceuticals reports net loss of $9.8 million for first quarter 2011

Pacira Pharmaceuticals, Inc., an emerging specialty pharmaceutical company, today announced financial results for the first quarter ended March 31, 2011, provided an update on the execution of its pre-commercial and launch strategies for EXPAREL, and reiterated 2011 financial guidance.

11 May 2011

Pacira to present EXPAREL data in postsurgical pain at two medical meetings

Pacira Pharmaceuticals, Inc., an emerging specialty pharmaceutical company, today announced that clinical and preclinical data highlighting the safety and efficacy of EXPAREL™ will be presented at two medical meetings.

6 May 2011

Special-focus on postoperative cognitive dysfunction in older adults

Postoperative cognitive dysfunction (POCD) refers to a "mild but possibly long-lasting cognitive fogginess" occurring after surgery and anesthesia. The May issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS), presents a special-focus section on POCD in older adults—including the possible causes and preoperative evaluation of POCD risk.

28 Apr 2011

The Lancet publishes phase 3 clinical study data on VIVITROL for treatment of opioid dependence

Alkermes, Inc. today announced that results from the phase 3 clinical study of VIVITROL® (naltrexone for extended-release injectable suspension) in opioid dependence have been published by The Lancet. The six-month, phase 3 trial met its primary endpoint and showed significantly greater opioid-free weeks among patients treated with VIVITROL, compared to placebo.

28 Apr 2011

Study clarifies ginkgo's pain-reducing effects

Experiments in rats show that a standardized ginkgo extract—injected either into the spinal canal or directly into the injured area—effectively reduces inflammation and some types of pain, according to a report in the May issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society.

28 Apr 2011

Nuvo Research to acquire ZARS Pharma

Nuvo Research Inc., a pharmaceutical company dedicated to building a portfolio of products primarily for the treatment of pain, today announced that it has entered into an agreement to acquire ZARS Pharma, Inc., a specialty pharmaceutical company based in Salt Lake City, Utah.

18 Apr 2011

ETI develops extended release SC depot formulation of NSAID drug meloxicam

Encore Therapeutics Inc. has developed a proprietary extended release subcutaneous (SC) depot formulation (ETI-511) of the NSAID drug meloxicam.

5 Apr 2011

Pacira reports net loss of $7.0 million for quarter ended December 31, 2010

Pacira Pharmaceuticals, Inc., an emerging specialty pharmaceutical company, today announced financial results for the fourth quarter and full-year ended December 31, 2010, provided an update on the execution of its pre-commercial and launch strategies for EXPAREL and established 2011 financial guidance.

31 Mar 2011

SpHb sensor can monitor blood hemoglobin levels during spine surgery

A spectrophotometric hemoglobin sensor may become a useful new approach to noninvasive monitoring of blood hemoglobin levels during surgery, reports a study in the April issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society.

29 Mar 2011

Challenges of high-risk surgery

A small group of "high-risk" patients account for a disproportionately high number of surgery-related deaths, complications, and costs. The April issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS), commences a special series on high-risk surgery—focusing on new and emerging strategies for identifying and managing patients at high risk.

28 Mar 2011

Purdue demonstrates efficacy of Butrans transdermal delivery system for chronic pain in opioid-naive patients

Physicians from Purdue Pharma LP, Stamford, CT, showcased study results that demonstrate the analgesic efficacy and safety of Butrans for the relief of moderate to severe chronic low back pain in opioid-naive patients. Butrans is a transdermal delivery system that provides systemic delivery of buprenorphine, a Schedule III medication, continuously over a 7-day period.

25 Mar 2011

Study examines regional analgesia effect on long-term outcomes in soldiers with combat injuries

Little is known about the impact of early aggressive regional analgesia on short- and long-term pain and psychological outcomes of soldiers with major combat injuries.

25 Mar 2011